Specifically, in the preclinical setting, DW-MRI has demonstrated utility as an early indicator of paclitaxel response based on measured decreases in tumor cellularity [21], and DCE-MRI has been utilized to measure trastuzumab-induced increases in vascular perfusion within HER2+ xenograft tumors [18]. The gene discussed is ERBB2; the disease is neoplasm.